These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 16359508)
1. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508 [TBL] [Abstract][Full Text] [Related]
2. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. Segers O; Simioni P; Tormene D; Bulato C; Gavasso S; Rosing J; Castoldi E J Thromb Haemost; 2012 Jan; 10(1):73-80. PubMed ID: 22044617 [TBL] [Abstract][Full Text] [Related]
3. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Castoldi E; Brugge JM; Nicolaes GA; Girelli D; Tans G; Rosing J Blood; 2004 Jun; 103(11):4173-9. PubMed ID: 14976057 [TBL] [Abstract][Full Text] [Related]
4. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance. Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446 [TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance. Guasch JF; Lensen RP; Bertina RM Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576 [TBL] [Abstract][Full Text] [Related]
6. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401 [TBL] [Abstract][Full Text] [Related]
7. A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, together with 1982_1983del). Shimonishi N; Morishita E; Ogiwara K; Maruyama K; Yoshida J; Horie K; Nogami K J Thromb Haemost; 2024 Oct; 22(10):2810-2822. PubMed ID: 38950780 [TBL] [Abstract][Full Text] [Related]
8. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565 [TBL] [Abstract][Full Text] [Related]
9. Factor V Leiden: a disorder of factor V anticoagulant function. Castoldi E; Rosing J Curr Opin Hematol; 2004 May; 11(3):176-81. PubMed ID: 15257017 [TBL] [Abstract][Full Text] [Related]
10. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. Castaman G; Tosetto A; Ruggeri M; Rodeghiero F Br J Haematol; 1999 Jul; 106(1):232-6. PubMed ID: 10444192 [TBL] [Abstract][Full Text] [Related]
11. Factor V and thrombotic disease: description of a janus-faced protein. Nicolaes GA; Dahlbäck B Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687 [TBL] [Abstract][Full Text] [Related]
12. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers. Mingozzi F; Legnani C; Lunghi B; Scanavini D; Castoldi E; Palareti G; Marchetti G; Bernardi F Thromb Haemost; 2003 Jun; 89(6):983-9. PubMed ID: 12783110 [TBL] [Abstract][Full Text] [Related]
13. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Dahlbäck B Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959 [TBL] [Abstract][Full Text] [Related]
15. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays. Delahousse B; Iochmann S; Pouplard C; Fimbel B; Charbonnier B; Gruel Y Blood Coagul Fibrinolysis; 1997 Nov; 8(8):503-9. PubMed ID: 9491268 [TBL] [Abstract][Full Text] [Related]
16. Determination of activated protein C resistance in anticoagulated and lupus positive patients. Ivey LM; Thom JY; Ivey JG; Baker RI Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805 [TBL] [Abstract][Full Text] [Related]
17. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Simioni P; Castoldi E; Lunghi B; Tormene D; Rosing J; Bernardi F Blood; 2005 Oct; 106(7):2363-5. PubMed ID: 15961511 [TBL] [Abstract][Full Text] [Related]
18. Reduced factor V concentration and altered FV1/FV2 ratio do not fully explain R2-associated APC-resistance. Govers-Riemslag JW; Castoldi E; Nicolaes GA; Tans G; Rosing J Thromb Haemost; 2002 Sep; 88(3):444-9. PubMed ID: 12353074 [TBL] [Abstract][Full Text] [Related]
19. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool. Thomassen MC; Castoldi E; Tans G; Magdeleyns EJ; Delaunoit C; Debusscher L; Van Assche KJ; Rosing J Haematologica; 2003 Oct; 88(10):1150-6. PubMed ID: 14555311 [TBL] [Abstract][Full Text] [Related]
20. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population]. Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]